Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Briclin: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Briclin - General Information

A broad-spectrum antibiotic derived from kanamycin. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

 

Pharmacology of Briclin

Briclin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

 

Briclin for patients

Patient Information:
Amikacin is potentially nephrotoxic, ototoxic and neurotoxic. Patient should
drink more fluid to minimize the chemical irritation to the kidney. Renal
function should be monitored before and during the course of the treatment.
Amikacin-induced ototoxicity is usually irreversible. Patient may not have any
symptoms. Patient may experience numbness, tingling, muscle twitching and
convultions because of the neurotoxicity.
If patient experiences any unusual signs or symptoms, please contact you doctor
immediately.

 

Briclin Interactions

No information provided.

 

Briclin Contraindications

A history of hypersensitivity to amikacin is a contraindication for its use. A history of hypersensitivity or serious toxic reactions to aminoglycosides may contraindicate the use of any other aminoglycoside because of the known cross-sensitivities of patients to drugs in this class.

 

Additional information about Briclin

Briclin Indication: For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Mechanism Of Action: Aminoglycosides like Briclin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Briclin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically Briclin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Drug Interactions: Atracurium The agent increases the effect of muscle relaxant Bumetanide Increased ototoxicity Ceforanide Increased risk of nephrotoxicity Cefotaxime Increased risk of nephrotoxicity Ceftazidime Increased risk of nephrotoxicity Ceftriaxone Increased risk of nephrotoxicity Cefuroxime Increased risk of nephrotoxicity Cefalotin Increased risk of nephrotoxicity Cephapirin Increased risk of nephrotoxicity Cisplatin Increased risk of nephrotoxicity Mivacurium The agent increases the effect of muscle relaxant Ethacrynic acid Increased ototoxicity Furosemide Increased ototoxicity Rocuronium The agent increases the effect of muscle relaxant Succinylcholine The agent increases the effect of muscle relaxant Tubocurarine The agent increases the effect of muscle relaxant Thalidomide Thalidomide increases the renal toxicity of the aminoglycoside Torasemide Increased ototoxicity Cefamandole Increased risk of nephrotoxicity Cefazolin Increased risk of nephrotoxicity Cefonicid Increased risk of nephrotoxicity Cefoperazone Increased risk of nephrotoxicity Cefotetan Increased risk of nephrotoxicity Cefoxitin Increased risk of nephrotoxicity Ceftizoxime Increased risk of nephrotoxicity Cefradine Increased risk of nephrotoxicity Doxacurium The agent increases the effect of muscle relaxant Gallamine Triethiodide The agent increases the effect of muscle relaxant Metocurine The agent increases the effect of muscle relaxant Pancuronium The agent increases the effect of muscle relaxant Pipecuronium The agent increases the effect of muscle relaxant Vecuronium The agent increases the effect of muscle relaxant Food Interactions: Not Available Generic Name: Amikacin Synonyms: Amikacin Sulfate; Amikacin Dihydrate; Amikacin Base; Amikacina [Inn-Spanish]; Amikacine [Inn-French]; Amikacinum [Inn-Latin]; ANTIBIOTIC BB-K8; BB-K8 Drug Category: Anti-Bacterial Agents; Aminoglycosides Drug Type: Small Molecule; Approved; Investigational Other Brand Names containing Amikacin: Amicacin; Amiglyde-V; Amikavet; Amikin; Briclin; Absorption: Rapidly absorbed after intramuscular administration Toxicity (Overdose): Not Available Protein Binding: 0-11% Biotransformation: Not Available Half Life: 2-3 hours Dosage Forms of Briclin: Liquid Intravenous Chemical IUPAC Name: (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide Chemical Formula: C22H43N5O13 Amikacin on Wikipedia: https://en.wikipedia.org/wiki/Amikacin Organisms Affected: Enteric bacteria and other eubacteria